questionsmedicales.fr
Techniques d'investigation
Méthodes
Groupes témoins
Groupes témoins : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
4
Groupes témoins
Méthodes de recherche
Groupes témoins
Évaluation des traitements
Groupes témoins
Critères d'inclusion
Groupes témoins
Essais cliniques
Symptômes
2
Groupes témoins
Symptômes
Évaluation des symptômes
Groupes témoins
Prévention
2
Prévention
Groupes témoins
Mesures préventives
Groupes témoins
Traitements
2
Traitements expérimentaux
Groupes témoins
Mesure des résultats
Groupes témoins
Complications
2
Complications
Groupes témoins
Analyse des complications
Groupes témoins
Facteurs de risque
2
Facteurs de risque
Groupes témoins
Évaluation des facteurs de risque
Groupes témoins
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Groupes témoins : Questions médicales les plus fréquentes",
"headline": "Groupes témoins : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Groupes témoins : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-25",
"dateModified": "2025-04-21",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Groupes témoins"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Méthodes",
"url": "https://questionsmedicales.fr/mesh/D008722",
"about": {
"@type": "MedicalCondition",
"name": "Méthodes",
"code": {
"@type": "MedicalCode",
"code": "D008722",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E05.581"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Groupes témoins",
"alternateName": "Control Groups",
"code": {
"@type": "MedicalCode",
"code": "D035061",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Thomas Steger-Hartmann",
"url": "https://questionsmedicales.fr/author/Thomas%20Steger-Hartmann",
"affiliation": {
"@type": "Organization",
"name": "Bayer Research & Development, Pharmaceuticals, Investigative Toxicology, Berlin, Germany."
}
},
{
"@type": "Person",
"name": "Tania Rivera-Hernandez",
"url": "https://questionsmedicales.fr/author/Tania%20Rivera-Hernandez",
"affiliation": {
"@type": "Organization",
"name": "School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, St. Lucia, Queensland, Australia."
}
},
{
"@type": "Person",
"name": "Mark J Walker",
"url": "https://questionsmedicales.fr/author/Mark%20J%20Walker",
"affiliation": {
"@type": "Organization",
"name": "School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, St. Lucia, Queensland, Australia."
}
},
{
"@type": "Person",
"name": "Mark R Davies",
"url": "https://questionsmedicales.fr/author/Mark%20R%20Davies",
"affiliation": {
"@type": "Organization",
"name": "Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia."
}
},
{
"@type": "Person",
"name": "Alexander Gurjanov",
"url": "https://questionsmedicales.fr/author/Alexander%20Gurjanov",
"affiliation": {
"@type": "Organization",
"name": "Bayer Research & Development, Pharmaceuticals, Investigative Toxicology, Berlin, Germany. Electronic address: alexander.gurjanov@bayer.com."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Key Factors Analysis of Severity of Automobile to Two-Wheeler Traffic Accidents Based on Bayesian Network.",
"datePublished": "2022-05-15",
"url": "https://questionsmedicales.fr/article/35627556",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph19106013"
}
},
{
"@type": "ScholarlyArticle",
"name": "Research on safety of the intended functionality of automobile AEB perception system in typical dangerous scenarios of two-wheelers.",
"datePublished": "2022-05-18",
"url": "https://questionsmedicales.fr/article/35597224",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.aap.2022.106709"
}
},
{
"@type": "ScholarlyArticle",
"name": "Driving Frequency Modulates Correlations Between Executive Functions and Driving Performance: A Driving Simulator Study.",
"datePublished": "2023-11-14",
"url": "https://questionsmedicales.fr/article/37962038",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/00315125231209646"
}
},
{
"@type": "ScholarlyArticle",
"name": "Feature selection for driving style and skill clustering using naturalistic driving data and driving behavior questionnaire.",
"datePublished": "2023-03-15",
"url": "https://questionsmedicales.fr/article/36931183",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.aap.2023.107022"
}
},
{
"@type": "ScholarlyArticle",
"name": "Modeling of older adults' driving exposure and avoidance using objective driving data in a naturalistic driving study.",
"datePublished": "2022-06-09",
"url": "https://questionsmedicales.fr/article/35689967",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.aap.2022.106728"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Techniques d'investigation",
"item": "https://questionsmedicales.fr/mesh/D008919"
},
{
"@type": "ListItem",
"position": 3,
"name": "Méthodes",
"item": "https://questionsmedicales.fr/mesh/D008722"
},
{
"@type": "ListItem",
"position": 4,
"name": "Groupes témoins",
"item": "https://questionsmedicales.fr/mesh/D035061"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Groupes témoins - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Groupes témoins",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Groupes témoins",
"description": "Comment identifier un groupe témoin ?\nQuel est le rôle d'un groupe témoin ?\nComment choisir un groupe témoin ?\nLes groupes témoins sont-ils toujours nécessaires ?",
"url": "https://questionsmedicales.fr/mesh/D035061?mesh_terms=Automobile+Driving#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Groupes témoins",
"description": "Les groupes témoins montrent-ils des symptômes ?\nComment les symptômes sont-ils évalués ?",
"url": "https://questionsmedicales.fr/mesh/D035061?mesh_terms=Automobile+Driving#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Groupes témoins",
"description": "Les groupes témoins aident-ils à la prévention ?\nComment les groupes témoins influencent-ils la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D035061?mesh_terms=Automobile+Driving#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Groupes témoins",
"description": "Quel type de traitement est comparé ?\nComment les résultats sont-ils mesurés ?",
"url": "https://questionsmedicales.fr/mesh/D035061?mesh_terms=Automobile+Driving#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Groupes témoins",
"description": "Les complications sont-elles observées dans les groupes témoins ?\nComment les complications sont-elles analysées ?",
"url": "https://questionsmedicales.fr/mesh/D035061?mesh_terms=Automobile+Driving#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Groupes témoins",
"description": "Les groupes témoins aident-ils à identifier des facteurs de risque ?\nComment les facteurs de risque sont-ils évalués ?",
"url": "https://questionsmedicales.fr/mesh/D035061?mesh_terms=Automobile+Driving#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un groupe témoin ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un groupe témoin est constitué de participants similaires au groupe traité, mais sans intervention."
}
},
{
"@type": "Question",
"name": "Quel est le rôle d'un groupe témoin ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il permet d'évaluer l'effet d'un traitement en comparant les résultats avec ceux du groupe traité."
}
},
{
"@type": "Question",
"name": "Comment choisir un groupe témoin ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le choix doit se baser sur des critères d'inclusion similaires à ceux du groupe traité."
}
},
{
"@type": "Question",
"name": "Les groupes témoins sont-ils toujours nécessaires ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont essentiels pour établir des comparaisons valides dans les études cliniques."
}
},
{
"@type": "Question",
"name": "Les groupes témoins montrent-ils des symptômes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, ils ne reçoivent pas de traitement, donc ils ne présentent pas de symptômes liés au traitement."
}
},
{
"@type": "Question",
"name": "Comment les symptômes sont-ils évalués ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes sont évalués par des questionnaires ou des examens cliniques dans les deux groupes."
}
},
{
"@type": "Question",
"name": "Les groupes témoins aident-ils à la prévention ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils permettent d'évaluer l'efficacité des interventions préventives par comparaison."
}
},
{
"@type": "Question",
"name": "Comment les groupes témoins influencent-ils la prévention ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils fournissent des données sur l'impact des mesures préventives en comparaison avec l'absence d'intervention."
}
},
{
"@type": "Question",
"name": "Quel type de traitement est comparé ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement expérimental est comparé à un placebo ou à un traitement standard dans le groupe témoin."
}
},
{
"@type": "Question",
"name": "Comment les résultats sont-ils mesurés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les résultats sont mesurés par des critères prédéfinis, comme l'amélioration des symptômes."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles observées dans les groupes témoins ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent être observées, mais elles ne sont pas dues au traitement expérimental."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles analysées ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont analysées en comparant leur fréquence entre le groupe témoin et le groupe traité."
}
},
{
"@type": "Question",
"name": "Les groupes témoins aident-ils à identifier des facteurs de risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils permettent de comparer les facteurs de risque entre les groupes traité et témoin."
}
},
{
"@type": "Question",
"name": "Comment les facteurs de risque sont-ils évalués ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont évalués par des questionnaires et des analyses statistiques dans les deux groupes."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 21/04/2025
Contenu vérifié selon les dernières recommandations médicales
5 publications dans cette catégorie
Affiliations :
Bayer Research & Development, Pharmaceuticals, Investigative Toxicology, Berlin, Germany.
Publications dans "Groupes témoins" :
2 publications dans cette catégorie
Affiliations :
School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, St. Lucia, Queensland, Australia.
Publications dans "Groupes témoins" :
2 publications dans cette catégorie
Affiliations :
School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, St. Lucia, Queensland, Australia.
Publications dans "Groupes témoins" :
2 publications dans cette catégorie
Affiliations :
Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Publications dans "Groupes témoins" :
2 publications dans cette catégorie
Affiliations :
Bayer Research & Development, Pharmaceuticals, Investigative Toxicology, Berlin, Germany. Electronic address: alexander.gurjanov@bayer.com.
Publications dans "Groupes témoins" :
2 publications dans cette catégorie
Affiliations :
Bayer Research & Development, Pharmaceuticals, Research & Pre-Clinical Statistics Group, Berlin, Germany.
Publications dans "Groupes témoins" :
2 publications dans cette catégorie
Affiliations :
KALOS Technologies, Philadelphia, Pennsylvania, USA.
Publications dans "Groupes témoins" :
2 publications dans cette catégorie
Affiliations :
Sanofi, Preclinical Safety, Frankfurt, Germany.
Publications dans "Groupes témoins" :
2 publications dans cette catégorie
Affiliations :
Merck Healthcare KGaA, Chemical & Preclinical Safety, Darmstadt, Germany.
Publications dans "Groupes témoins" :
2 publications dans cette catégorie
Affiliations :
Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland.
Publications dans "Groupes témoins" :
1 publication dans cette catégorie
Affiliations :
Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Publications dans "Groupes témoins" :
1 publication dans cette catégorie
Affiliations :
Scripps Institution of Oceanography, University of California San Diego, La Jolla, CA, USA.
Irset Institut de Recherche en Santé, Environnement et Travail, Inserm, University of Rennes, EHESP, Rennes, France.
Publications dans "Groupes témoins" :
1 publication dans cette catégorie
Affiliations :
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Publications dans "Groupes témoins" :
1 publication dans cette catégorie
Affiliations :
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Publications dans "Groupes témoins" :
1 publication dans cette catégorie
Affiliations :
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Publications dans "Groupes témoins" :
1 publication dans cette catégorie
Affiliations :
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Publications dans "Groupes témoins" :
1 publication dans cette catégorie
Affiliations :
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Publications dans "Groupes témoins" :
1 publication dans cette catégorie
Affiliations :
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Publications dans "Groupes témoins" :
1 publication dans cette catégorie
Affiliations :
College of Materials Science and Engineering, Hunan University Changsha Hunan 410082 China.
Publications dans "Groupes témoins" :
1 publication dans cette catégorie
Affiliations :
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Publications dans "Groupes témoins" :
The purpose of this paper is to analyze the complex coupling relationships among accident factors contributing to the automobile and two-wheeler traffic accidents by establishing the Bayesian network ...
The statistical analysis was conducted on data of accident scenarios between cars and two-wheelers from National Automobile Accident In-depth Investigation System (NAIS) database in order to study saf...
Driving a car requires a complex combination of various cognitive functions (e.g., visual perception, motor control, decision making, and others), and deficits in any of these processes may compromise...
Driver's driving style and driving skill have an essential influence on traffic safety, capacity, and efficiency. Through clustering algorithms, extensive studies explore the risk assessment, classifi...
Older adults in the United States rely heavily on driving their own vehicles to commute to work, shop for groceries, and access public services. To effectively help older adults maintain mobility and ...
Road safety is increasingly threatened by distracted driving. Studies have shown that there is a significantly increased risk for a driver of being involved in a car crash due to visual distractions (...
In-vehicle intersection warning systems represent a promising approach for informing drivers of potential danger to reduce crashes and improve intersection safety. However, there is limited research o...
Distracted driving is a growing concern around the world and has been the focus of many naturalistic and simulator-based studies. Driving simulators provide excellent practical and theoretical help in...
It is often assumed that consumers want partial driving automation in their vehicles, yet there has been little research on the topic. Also unclear is what the public's appetite is for hands-free driv...
Through an internet-based survey of a nationally representative sample of 1,010 U.S. adult drivers, this study explored consumer demand for different aspects of partial driving automation....
Eighty percent of drivers want to use lane centering, but more prefer versions with a hands-on-wheel requirement (36%) than hands-free (27%). More than half of drivers are comfortable with different d...
Consumers are interested in partial driving automation, but there is resistance to more sophisticated functionality, especially vehicle-initiated auto lane change, in a vehicle that cannot technically...
This study confirms the public's appetite for partial driving automation and possible intention for misuse. It is imperative that the technology be designed in ways that deter such misuse. The data su...
Eco-driving guidance refers to courses, warnings, or suggestions provided to human drivers to improve driving behaviour to enable less energy use and emissions. This paper reviews existing eco-driving...